Lipid Measurements in the Management of Cardiovascular Diseases: Practical Recommendations

Almost every cardiovascular decision begins with a lipid panel, yet the panel itself is more fraught than patients realize — affected by whether you fasted, by how LDL is calculated, by which marker is chosen. This National Lipid Association statement is a practical manual for getting that first step right.

It walks through the full arc of lipid testing — the pre-analytical questions (Is fasting necessary? mostly no), the analytical ones (How is LDL derived, and when does the old Friedewald calculation fail?), and the post-analytical ones (Which number should actually guide treatment?). Its through-line is that the standard LDL-C value, useful as it is, has real blind spots — particularly at low levels and high triglycerides — and that non-HDL cholesterol and apolipoprotein B offer a more complete count of atherogenic particles. It also situates the advanced tests, including lipoprotein(a), within sensible clinical use.

The document’s quiet importance is that it equips a patient or clinician to read a lipid report critically rather than at face value — to know when the LDL number can be trusted and when a better marker should be ordered.

The honest qualifier is that this is consensus guidance on measurement and interpretation, not an outcomes study; its recommendations reflect the writing group’s synthesis of best laboratory and clinical practice.

We rate the evidence strong. It is a thorough, well-referenced, and genuinely practical guide — the kind of document that improves care not by introducing a new therapy but by making sure the measurements every therapy depends on are sound.